Sample Size Esti­mate in BE Studies [Power / Sample Size]

posted by Sereng  – USA, 2022-05-12 17:22 (48 d 01:01 ago) – Posting: # 22976
Views: 405

Dear colleagues, in BE studies that must be conducted as parallel group design (e.g., depot formulations with sampling for 2 to 3 months), (i) is the sample size generally the same when compared to crossover design studies? and (ii) how do you estimate sample size when the known CV of the reference drug is excessive and much higher (e.g., double or triple) than the estimated CV of the Test drug? Regards

Biostatistically Challenged CEO

Complete thread:

UA Flag
 Admin contact
22,181 posts in 4,647 threads, 1,572 registered users;
online 7 (0 registered, 7 guests [including 7 identified bots]).
Forum time: Wednesday 18:24 CEST (Europe/Vienna)

Nerds don’t just happen to dress informally.
They do it too consistently.
Consciously or not, they dress informally
as a prophylactic measure against stupidity.    Paul Graham

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz